Structural biology of SARS-CoV-2 and implications for therapeutic development
- PMID: 34535791
- PMCID: PMC8447893
- DOI: 10.1038/s41579-021-00630-8
Structural biology of SARS-CoV-2 and implications for therapeutic development
Abstract
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for treatment are still very limited. The development of drugs that target vital proteins in the viral life cycle is a feasible approach for treating COVID-19. Belonging to the subfamily Orthocoronavirinae with the largest RNA genome, SARS-CoV-2 encodes a total of 29 proteins. These non-structural, structural and accessory proteins participate in entry into host cells, genome replication and transcription, and viral assembly and release. SARS-CoV-2 proteins can individually perform essential physiological roles, be components of the viral replication machinery or interact with numerous host cellular factors. In this Review, we delineate the structural features of SARS-CoV-2 from the whole viral particle to the individual viral proteins and discuss their functions as well as their potential as targets for therapeutic interventions.
© 2021. Springer Nature Limited.
Conflict of interest statement
The authors declare no competing interests.
Figures







Similar articles
-
Structural biology of SARS-CoV-2: open the door for novel therapies.Signal Transduct Target Ther. 2022 Jan 27;7(1):26. doi: 10.1038/s41392-022-00884-5. Signal Transduct Target Ther. 2022. PMID: 35087058 Free PMC article. Review.
-
Structural insights into SARS-CoV-2 proteins.J Mol Biol. 2021 Jan 22;433(2):166725. doi: 10.1016/j.jmb.2020.11.024. Epub 2020 Nov 24. J Mol Biol. 2021. PMID: 33245961 Free PMC article. Review.
-
Overview of SARS-CoV-2 genome-encoded proteins.Sci China Life Sci. 2022 Feb;65(2):280-294. doi: 10.1007/s11427-021-1964-4. Epub 2021 Aug 10. Sci China Life Sci. 2022. PMID: 34387838 Free PMC article. Review.
-
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.Cells. 2021 Apr 6;10(4):821. doi: 10.3390/cells10040821. Cells. 2021. PMID: 33917481 Free PMC article. Review.
-
SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?Curr Mol Med. 2022;22(1):50-66. doi: 10.2174/1566524021666210223143243. Curr Mol Med. 2022. PMID: 33622224 Review.
Cited by
-
Decoding the intricacies: a comprehensive analysis of microRNAs in the pathogenesis, diagnosis, prognosis and therapeutic strategies for COVID-19.Front Med (Lausanne). 2024 Oct 7;11:1430974. doi: 10.3389/fmed.2024.1430974. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39434774 Free PMC article. Review.
-
A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.Pharmaceuticals (Basel). 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891. Pharmaceuticals (Basel). 2024. PMID: 39065742 Free PMC article.
-
Endocytosis inhibitors block SARS-CoV-2 pseudoparticle infection of mink lung epithelium.Front Microbiol. 2023 Nov 14;14:1258975. doi: 10.3389/fmicb.2023.1258975. eCollection 2023. Front Microbiol. 2023. PMID: 38033586 Free PMC article.
-
Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase.Chem Sci. 2024 Jun 3;15(26):10065-10072. doi: 10.1039/d3sc06961c. eCollection 2024 Jul 3. Chem Sci. 2024. PMID: 38966375 Free PMC article.
-
Recent advances in chemometric modelling of inhibitors against SARS-CoV-2.Heliyon. 2024 Jan 9;10(2):e24209. doi: 10.1016/j.heliyon.2024.e24209. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38293468 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous